As of 2021, there are more biologics in clinical trials compared to small molecules. According to a report by the Pharmaceutical Research and Manufacturers of America (PhRMA), in 2020, there were 6,895 biologics in clinical trials, compared to 3,819 small molecules.
Trend moving towards biologics
The trend of increasing clinical trials for biologics has been ongoing for several years. This is because biologics have shown great potential in treating a wide range of diseases, including cancer, autoimmune disorders, and infectious diseases. They are also less likely to cause side effects and drug interactions than small molecules, which has led to increased interest in their development.
Small molecules are still relevant
However, it’s worth noting that the number of small molecules in clinical trials is still significant, and small molecules remain an important area of research in drug development. Small molecules have been used successfully to treat a wide range of diseases, including diabetes, hypertension, and depression, among others. Furthermore, small molecules are generally easier to manufacture and administer than biologics, which can be an advantage in some situations.
Overall, the relative number of biologics and small molecules in clinical trials reflects the ongoing shift towards biologic drug development, while also highlighting the continued importance of small molecule research in drug discovery.
